Strumento inattivo

Altre lingue PharmaCyte Biotech, Inc. Other OTC

Azioni

PMCB

US71715X1046

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease	21/05
PharmaCyte Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024	18/03
PharmaCyte Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2023	15/12
Femasys Inc. announced that it has received $6.85 million in funding from PharmaCyte Biotech, Inc. and other investors	22/11
Femasys Inc. announces tranche update	17/11
PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women's Health Innovator Femasys, Inc.	16/11
PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women’s Health Innovator Femasys, Inc.	15/11
Femasys Inc. announced that it expects to receive $6.85 million in funding from PharmaCyte Biotech, Inc.	14/11
PharmaCyte Biotech : Change in Certifying Accountants - Form 8-K	10/11
PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology	31/10/23
PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology	31/10/23
PharmaCyte Biotech, Inc. Provides Corporate Update on Cell-In-A-Box Technology	31/10/23
Tranche Update on PharmaCyte Biotech, Inc.'s Equity Buyback Plan announced on February 2, 2023.	18/09/23
PharmaCyte Biotech, Inc. Reports Earnings Results for the First Quarter Ended July 31, 2023	18/09/23
PharmaCyte Biotech : Certificate of Incorporation/Bylaws - Form 8-K	07/09/23
Tranche Update on PharmaCyte Biotech, Inc.'s Equity Buyback Plan announced on February 2, 2023.	31/07/23
PharmaCyte Biotech, Inc. Reports Earnings Results for the Full Year Ended April 30, 2023	31/07/23
Tranche Update on PharmaCyte Biotech, Inc.'s Equity Buyback Plan announced on May 11, 2023.	15/06/23
PharmaCyte Biotech Announces Final Results of Tender Offer	15/06/23
PharmaCyte Biotech, Inc.'s Equity Buyback announced on May 11, 2023, has closed with 8,085,879 shares, representing 48.15% for $26.46 million.	09/06/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue PharmaCyte Biotech, Inc. Other OTC

Azioni

PMCB

US71715X1046

Altre lingue

Filtri